NCT00058526 - A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 20, 2003

Primary Completion Date

September 6, 2006

Study Completion Date

September 6, 2006

Conditions

Neoplasms, Breast

Interventions

BIOLOGICAL

Immunotherapeutic SB719125 (Primary)

Intramuscular injection

Trial Locations (17)

1000

GSK Investigational Site, Brussels

1200

GSK Investigational Site, Brussels

3000

GSK Investigational Site, Leuven

3002

GSK Investigational Site, East Melbourne

3011

GSK Investigational Site, Footscray

3084

GSK Investigational Site, Heidelberg

6000

GSK Investigational Site, Charleroi

14263

GSK Investigational Site, Buffalo

20141

GSK Investigational Site, Milan

28203

GSK Investigational Site, Charlotte

33428

GSK Investigational Site, Boca Raton

44805

GSK Investigational Site, Saint-Herblain

69373

GSK Investigational Site, Lyon

75248

GSK Investigational Site, Paris

98195

GSK Investigational Site, Seattle

00161

GSK Investigational Site, Rome

06156

GSK Investigational Site, Perugia